He discusses Insmed, IDEAYA, Bicycle, Compass Pathways, Revolution Medicines, Cytokinetics, and CG Oncology Chapters General sentiment - 1:25 Insmed - 3:16 IDEAYA - 7:07 Bicycle - 9:44 Compass Pathways - 13:04 Revolution, Cytokinetics, CG - 16:03

She highlights the goal of the accelerator, which meets monthly online, and also will have an in-person symposium in October. Plus, science that interests her, including "nodal" biologic pathways. Learn more about the Ladders to Cures Scientific Accelerator

She highlights a bill she has filed to help fill the gap left by reduced federal funding for research, and also the non-monetary initiatives, like quality of life, that the state can do to retain talent.

Michal Preminger will lead BioMed X Venture labs as CEO, and it will partner with pharma, foundations, and VCs to build mission driven companies.

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Zag Bio CEO Jason Cole and Altido Therapeutics CEO Chip Clark about running early stage companies and what advice they have for new CEOs. They offer advice about what it will take to keep our ecosystem globally competitive. Chapters Zag Bio - 1:03 Altido Therapeutics - 2:12 Massachusetts - 3:00 Culture- 5:11 Different skill sets - 7:11 Getting through challenge - 9:12 Early stage companies - 15:27 F

He talks about Syncona's listed fund, and clarifies the details of a return of capital strategy for some shareholders, and he describes the strategy of the firm's new private fund. Plus, how Syncona thinks about opportunities in life sciences today.

He shares his take on topics such as how the Baby KJ news is allowing investors and companies to think about scaling bespoke therapies, how AI might start to impact the clinical trial side of our business, and why he sees pharma adoption of AI as being important.

He comments on Abivax, Corvus, Iovance, Legend, Terns, and more. Chapters General sentiment - 0:48 Abivax - 2:14 Corvus - 5:46 Iovance - 7:32 Legend - 9:56 Terns - 11:47

She discusses uniQure, Moderna, BridgeBio, Gossamer Bio and more. Chapters General take on biotech - 0:36 uniQure - 1:43 Moderna - 4:34 BridgeBio - 7:04 Gossamer Bio - 8:07 Other catalysts - 9:36

He believes that the sector's fundamentals are strong and that M&A, which played a central role in boosting biotech last year, can keep up in 2026. Plus, he believes there is a good supply of quality IPOs in the queue that can meet demand that has been there for a while.

He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.

He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Aurora Therapeutics CEO Ed Kaye and DaCapo Brainscience CEO Leslie Williams about being biotech leaders during this volatile time for the industry. They stress that a key to success is that everyone in the industry work together towards shared goals. Chapters Introductions - 1:19 Aurora Therapeutics - 5:34 DaCapo Brainscience - 9:37 Being patient centric - 11:00 The state of the industry - 19:04 Mas

He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take on the recent Corvus atopic dermatitis data. Chapters IDEAYA Biosciences - 0:46 EyePoint / Ocular - 3:45 Palvella - 7:43 Corvus - 12:30

MLSC's President & CEO Kirk Taylor, MD describes the organization's mission, how biotech startups and others can search for and utilize equipment and facilities that might otherwise be out of reach, and his take on the current state of the ecosystem.